The Claim
In patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), the LIVER-ASCVD+ model stratifies individuals into distinct high- and low-risk categories for 10-year cardiovascular events, with significantly different incidence rates of myocardial infarction, stroke, and death compared to standard risk models.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with biopsy-confirmed MASH, the LIVER-ASCVD+ model identifies groups with higher and lower rates of heart attack, stroke, and death over 10 years, and these rates differ significantly from those predicted by standard risk models.
See the scientific wording
In patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH), the LIVER-ASCVD+ model stratifies individuals into distinct high- and low-risk categories for 10-year cardiovascular events, with significantly different incidence rates of myocardial infarction, stroke, and death compared to standard risk models.
Fat-damaged liver cells release signals that cause blood vessels to stiffen and become inflamed, which increases the chance of heart attacks, strokes, and death over time.
What the research says
1 studyThis new tool, called LIVER-ASCVD+, does a better job than old methods at guessing who among people with severe fatty liver disease will have a heart attack or stroke in the next 10 years. It uses extra liver info to make smarter predictions.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.